Abstracts tagged "polymerase chain reaction (PCR) and rheumatoid arthritis (RA)"

Abstract Number: 1563 • 2016 ACR/ARHP Annual Meeting
Enhanced Expression of mRNA for Response Gene to Complement 32 in CD34+ Cells of the Bone Marrow in Rheumatoid Arthritis
Yu Matsueda¹, Tatsuo Nagai², Tetsuya Tomita³, Hideki Yoshikawa³, Sumiaki Tanaka¹ and Shunsei Hirohata¹, ¹Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ²Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan, ³Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by hyperplasia of synovial lining cells, consisting of macrophage-like type A synoviocytes and fibroblast-like type…
Abstract Number: 522 • 2015 ACR/ARHP Annual Meeting
The Expression of mRNA for Peptidylarginine Deiminase Type 2 and Type 4 in CD34+ Cells of the Bone Marrow in Rheumatoid Arthritis
Tatsuo Nagai¹, Tetsuya Tomita², Hideki Yoshikawa² and Shunsei Hirohata¹, ¹Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ²Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan
Background/Purpose: We previously showed that bone marrow (BM) CD34+ cells from rheumatoid arthritis (RA) patients have abnormal capacities to respond to tumor necrosis factor alpha…
Abstract Number: 2427 • 2013 ACR/ARHP Annual Meeting
Enhanced Expression Of mRNA For Triggering Receptor Expressed On Myeloid Cells 1 In CD34+ Cells Of The Bone Marrow In Rheumatoid Arthritis
Tatsuo Nagai¹, Tetsuya Tomita², Hideki Yoshikawa² and Shunsei Hirohata³, ¹Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan, ²Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Japan, ³Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan
Background/Purpose: We previously showed that bone marrow (BM) CD34+ cells from rheumatoid arthritis (RA) patients have abnormal capacities to respond to tumor necrosis factor alpha…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].